Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
The authors report two cases of successful employment of human recombinant activated factor VII in gynecological oncological patients (endometrial cancer and vaginal sarcoma) without pre-existing coagulopathy. They conclude that recombinant factor VIIa may be an important and effective drug in severe bleeding in gynecological oncology.
Sajdak
S
S
Department of Gynecology and Obstetrics, Karol Marcinkowski University of Medical Sciences, Poznan, Poland. Kgo@gpsk.am.poznan.pl
Moszynski
R
R
Opala
T
T
D000230:Adenocarcinoma / Q000150:complications / Q000532:radiotherapy; D000282:Administration, Intravaginal; D000328:Adult; D000368:Aged; D016889:Endometrial Neoplasms / Q000150:complications / Q000532:radiotherapy; D004979:Ethamsylate / Q000008:administration & dosage; D005168:Factor VII Deficiency / Q000150:complications / Q000188:drug therapy*; D015942:Factor VIIa / Q000008:administration & dosage*; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D008339:Mandibular Neoplasms / Q000150:complications / Q000556:secondary / Q000628:therapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins; D012509:Sarcoma / Q000150:complications / Q000556:secondary / Q000628:therapy; D014148:Tranexamic Acid / Q000008:administration & dosage; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D014625:Vaginal Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy
D006490:Hemostatics; D011994:Recombinant Proteins; D004979:Ethamsylate; D014148:Tranexamic Acid; D015942:Factor VIIa